An observational study in Functional Neurological Disorders and Multiple Sclerosis, sponsored by University Hospital, Strasbourg, France. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by University Hospital, Strasbourg, France · Observational
Multiple sclerosis (MS) and functional neurological disorders (FND) share clinical features, which may result in FND being overlooked in patients with MS. They also share common comorbidities, including depression and alexithymia.
As their management differs, assessing the frequency and determinants of FND in patients with MS is important to improve diagnosis and ensure appropriate management.
Multiple sclerosis (MS) and functional neurological disorders (FND) share clinical features, which may result in FND being overlooked in patients with MS. They also share common comorbidities, including depression and alexithymia.
As their management differs, assessing the frequency and determinants of FND in patients with MS is important to improve diagnosis and ensure appropriate management.
During a routine medical visit, eligible patients will be informed about the study and invited to participate.
The two participating centers, located in Strasbourg and Nancy, each have an active cohort allowing the required number of participants to be recruited within one year.
Exclusion Criteria:
Assessment of the frequency of TNF in patients with multiple sclerosis
Assessment of the frequency of TNF in patients with multiple sclerosis
Time frame: day0
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France